News
Apnimed Achieves Meaningful Results in Proof-of-Concept Crossover Study with Oral Therapeutic Candidates AD504 and AD182 for the Treatment of Obstructive Sleep Apnea
Apnimed announces positive results from a proof-of-concept crossover study in patients with OSA evaluating AD504 and AD182.
Apnimed Announces Positive Phase 2 Data (Study APC-004) Demonstrating Improvement in Measures of Obstructive Sleep Apnea and a Dose-Response with AD109, an Oral Pharmacologic Treatment for the Disease
Apnimed today announced positive data across multiple endpoints from its Phase 2 randomized, double-blind, placebo-controlled, crossover clinical trial (Study APC-004) evaluating the efficacy and safety of AD109 as a treatment for patients with mild to moderate OSA.
Apnimed Announces Positive Phase 2 (Study APC-003) Data Demonstrating Durability-of-Effect and Improved Quality-of-Life in Patients with Obstructive Sleep Apnea After Investigational AD109 Treatment
Apnimed announced positive data across multiple endpoints from a Phase 2 randomized, double-blind, placebo-controlled, four-period, single-dose crossover factorial clinical trial (APC-003), and a 28-day open-label extension study, evaluating AD109 as a treatment in patients with mild to severe OSA.
Apnimed Expands Executive Leadership Team Appointing Rob Rode Chief Commercial Officer
Apnimed, a clinical-stage company focused on advancing pharmacologic treatments for obstructive sleep apnea and related disorders, today announced that Rob Rode has joined the company as Chief Commercial Officer. Mr. Rode has more than 27 years of experience leading global sales and marketing efforts in the biopharmaceutical field and will be responsible for developing and executing Apnimed’s commercial strategy.
Apnimed to Present at the Canaccord Genuity 41st Annual Growth Conference
The Apnimed management team will participate in the Canaccord Genuity Virtual 41st Annual Growth Conference on August 12-13, 2021.
David P. White, M.D. Appointed Senior Vice President of Medical Affairs at Apnimed
Apnimed, a clinical-stage company focused on advancing pharmacologic treatments for obstructive sleep apnea and related disorders, today announced that David P. White, M.D., a world-renowned leader in sleep disorders has been appointed Senior Vice President of Medical Affairs.
Apnimed to Present at the Ladenburg Thalmann Virtual Healthcare Conference
CAMBRIDGE, Mass. July 6, 2021 – Apnimed, a clinical-stage pharmaceutical company focused on developing oral medicines to treat Obstructive Sleep Apnea (OSA) and related disorders, today announced that the Company’s management team will participate in the Ladenburg...
Apnimed to Present at the Jefferies Virtual Healthcare Conference
CAMBRIDGE, Mass. May 25, 2021 – Apnimed, a clinical-stage pharmaceutical company focused on developing oral medicines to treat Obstructive Sleep Apnea (OSA) and related disorders, today announced that the Company’s management team will participate in the Jefferies Virtual Healthcare Conference, held June 1-4, 2021. Apnimed’s presentation is scheduled for Tuesday, June 1st at 4:30pm ET. Management will be available June 1st throughout the day for virtual one-on-one meetings.
New Data Presented at American Thoracic Society Meeting Reinforces the Potential of an Oral Drug Combination Therapy for the Treatment of Obstructive Sleep Apnea
CAMBRIDGE, Mass. May 17, 2021 – Apnimed, a clinical-stage company focused on advancing pharmacologic treatments for sleep apnea and related disorders, announced today that researchers from Istituto Auxologico Italiano and Brigham and Women’s Hospital presented data on the company’s investigational treatment for obstructive sleep apnea, AD128, at the American Thoracic Society (ATS) Meeting, taking place from May 14-19, 2021.
Apnimed to Present at the 20th Annual Needham Virtual Healthcare Conference
Apnimed, a clinical-stage pharmaceutical company focused on developing oral medicines to treat Obstructive Sleep Apnea (OSA) and related disorders, today announced that the Company’s management team will participate in the 20th Annual Needham Virtual Healthcare Conference, held April 12-15, 2021. Apnimed’s presentation is scheduled for Thursday, April 15th at 3:45 pm ET.
GET APNIMED UPDATES